We are live on ! Find out more
GRCE

Grace Therapeutics
GRCE

13 hedge funds and large institutions have $2.29M invested in Grace Therapeutics in 2018 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

377% more capital invested

Capital invested by funds: $479K → $2.29M (+$1.81M)

300% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 2

86% more funds holding

Funds holding: 7 → 13 (+6)

0.05% more ownership

Funds ownership: 0.02% → 0.07% (+0.05%)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
13
Holders Change
+6
Holders Change %
+85.71%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
1
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$1.62M
2
SM
Sabby Management
Florida
+$250K
3
PVI
Pura Vida Investments
New York
+$171K
4
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$84.7K
5
Citadel Advisors
Citadel Advisors
Florida
+$54.7K

Top Sellers

Rank Fund Capital Flow
1
IIM
Intact Investment Management
Quebec, Canada
-$81K
2
Renaissance Technologies
Renaissance Technologies
New York
-$79K
3
FDCDDQ
Federation des caisses Desjardins du Quebec
Quebec, Canada
-$10.9K
4
Morgan Stanley
Morgan Stanley
New York
-$1.88K
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
1
Perceptive Advisors
New York
$1.48M +$1.62M +37,081 New
SM
2
Sabby Management
Florida
$229K +$250K +5,729 New
Bank of Montreal
3
Bank of Montreal
Ontario, Canada
$206K +$84.7K +1,942 +60%
PVI
4
Pura Vida Investments
New York
$157K +$171K +3,922 New
Citadel Advisors
5
Citadel Advisors
Florida
$50K +$54.7K +1,255 New
Geode Capital Management
6
Geode Capital Management
Massachusetts
$40K +$44.2K +1,014 New
Morgan Stanley
7
Morgan Stanley
New York
$32K -$1.88K -43 -5%
Bank of America
8
Bank of America
North Carolina
$31K +$34.3K +787 New
FDCDDQ
9
Federation des caisses Desjardins du Quebec
Quebec, Canada
$31K -$10.9K -250 -24%
KJHP
10
K.J. Harrison & Partners
Ontario, Canada
$28K +$30.9K +708 New
Royal Bank of Canada
11
Royal Bank of Canada
Ontario, Canada
$3K – – –
RE
12
RBC Europe
United Kingdom
$25 – – –
Renaissance Technologies
13
Renaissance Technologies
New York
– -$79K -1,275 Closed
IIM
14
Intact Investment Management
Quebec, Canada
– -$81K -1,021 Closed
Toronto Dominion Bank
15
Toronto Dominion Bank
Ontario, Canada
– +$44 +1 New

GRCE Hedge Fund Activity: Q4 2018 in Review

13 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q4 2018, worth a combined $2.29M — up 377% from $479K a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new GRCE positions and 2 closed out — a net gain of 6 holders — while 1 added to existing stakes and 2 trimmed.

The largest buyer was Perceptive Advisors, opening a new position worth an estimated $1.62M. The largest seller was Intact Investment Management, exiting entirely with an estimated $81K sold.

  • 13 institutional investors held Grace Therapeutics (GRCE) as of Q4 2018, up from 7 in Q3 2018.
  • Funds reported $2.29M of Grace Therapeutics stock for Q4 2018, up 377% quarter-over-quarter.
  • 8 funds opened new Grace Therapeutics positions in Q4 2018 and 2 closed out, a net change of +6 holders.
  • The largest Grace Therapeutics buyer in Q4 2018 was Perceptive Advisors, an estimated $1.62M added.
  • The largest Grace Therapeutics seller in Q4 2018 was Intact Investment Management, an estimated $81K sold.

Based on aggregated 13F filings for Q4 2018.